tiprankstipranks
Trending News
More News >
Active Biotech AB (SE:ACTI)
:ACTI

Active Biotech AB (ACTI) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Active Biotech AB

(Frankfurt:ACTI)

Rating:32Underperform
Price Target:
Active Biotech AB's financial struggles are the most significant factor in its low stock score. The lack of revenue and persistent losses pose substantial risks, despite a stable debt level. Technical indicators do not suggest any immediate recovery, and the negative valuation metrics further underscore the challenges faced by the company.

Active Biotech AB (ACTI) vs. iShares MSCI Sweden ETF (EWD)

Active Biotech AB Business Overview & Revenue Model

Company DescriptionActive Biotech AB (ACTI) is a Swedish biotechnology company specializing in the development of pharmaceuticals for the treatment of autoimmune and inflammatory diseases, as well as cancer. The company focuses on research and development to create innovative therapies that address unmet medical needs. Active Biotech's core products include drug candidates in various stages of clinical trials, targeting conditions such as multiple sclerosis, cancer, and inflammatory diseases.
How the Company Makes MoneyActive Biotech AB generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. These partnerships often involve licensing agreements, where Active Biotech licenses its drug candidates to partners for further development and commercialization. In return, Active Biotech receives upfront payments, milestone payments based on the achievement of specific developmental or regulatory milestones, and royalties on future sales of the licensed products. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials, as well as the ability to secure and maintain strategic partnerships with industry leaders.

Active Biotech AB Financial Statement Overview

Summary
Active Biotech AB faces significant financial challenges, with no revenue generation and persistent losses. The low debt level on the balance sheet is positive, but the negative cash flow and lack of revenue are critical concerns, highlighting the need for better financial stability.
Income Statement
15
Very Negative
Active Biotech AB has consistently reported zero revenue for the past several years, indicating a lack of commercial success or monetization in its operations. The company has been operating at a net loss, with substantial negative EBIT and EBITDA margins, reflecting challenges in cost management and scalability. The absence of revenue growth and negative profit margins further highlight significant financial hurdles.
Balance Sheet
40
Negative
The company has maintained a low debt level, with Total Debt being zero in the latest report, which is a positive indication of financial prudence. The Stockholders' Equity has remained relatively stable, indicating a reasonable equity base. However, the overall equity ratio is moderate, suggesting a balanced but not overly strong financial position. Despite these strengths, the lack of revenue generation remains a critical concern.
Cash Flow
20
Very Negative
Active Biotech AB has been experiencing negative free cash flow, which reflects ongoing operational losses and insufficient cash generation to cover costs. The substantial operating cash outflows indicate a challenging environment for achieving profitability. Although financing cash flows have been positive, suggesting some external capital influx, the dependency on such measures is not sustainable in the long term.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.006.72M
Gross Profit0.00-1.68M-1.49M-1.28M6.72M
EBITDA-39.90M-43.89M-56.67M-48.52M-30.84M
Net Income-39.40M-45.80M-58.69M-49.88M-32.12M
Balance Sheet
Total Assets43.20M44.05M51.01M56.80M32.16M
Cash, Cash Equivalents and Short-Term Investments27.40M36.22M41.80M53.13M26.21M
Total Debt0.004.54M6.04M986.00K2.00M
Total Liabilities11.13M13.38M16.49M10.13M10.04M
Stockholders Equity32.07M30.67M34.51M46.67M22.11M
Cash Flow
Free Cash Flow-40.40M-45.74M-55.09M-46.17M-32.22M
Operating Cash Flow-40.40M-45.74M-54.85M-46.17M-32.22M
Investing Cash Flow0.000.00-245.00K0.000.00
Financing Cash Flow31.60M40.16M43.76M73.09M-1.25M

Active Biotech AB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.19
Price Trends
50DMA
0.16
Positive
100DMA
0.13
Positive
200DMA
0.14
Positive
Market Momentum
MACD
<0.01
Positive
RSI
46.97
Neutral
STOCH
26.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Neutral. The current price of 0.19 is below the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.16, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.97 is Neutral, neither overbought nor oversold. The STOCH value of 26.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACTI.

Active Biotech AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
kr70.83M-126.57%36.91%49.66%
50
Neutral
kr5.39B12.66-80.61%5.12%37.36%27.71%
46
Neutral
kr97.19M-151.10%230.57%46.64%
39
Underperform
kr223.96M
-8.47%
34
Underperform
€105.91M-56.71%35.61%
32
Underperform
kr236.19M-186.40%24.47%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ACTI
Active Biotech AB
0.19
-0.03
-14.67%
SE:ATORX
Alligator Bioscience AB
6.35
-84.96
-93.04%
SE:BIOSGN
Biosergen AB
0.50
0.13
34.76%
SE:BIOVIC.B
Biovica International AB Class B
0.78
-1.70
-68.39%
SE:NICA
Nanologica AB
1.11
-4.80
-81.22%

Active Biotech AB Corporate Events

Active Biotech AB Announces 2025 Annual General Meeting
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without distributing dividends. This meeting is significant for stakeholders as it addresses the company’s governance and financial strategy moving forward.

Active Biotech Announces 2025 AGM and Board Re-elections
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address standard AGM procedures including the election of board members and auditors, with the re-election of current board members and auditors proposed. The company has decided not to distribute dividends, opting instead to carry forward accumulated losses.

Active Biotech AB Announces 2025 Annual General Meeting
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Key agenda items include the re-election of board members and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the company’s auditor, with no changes to the board’s remuneration.

Active Biotech AB Announces 2025 Annual General Meeting
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address various resolutions, including the re-election of board members and auditors, and the proposal to carry forward the company’s accumulated loss without paying dividends. This AGM is significant for stakeholders as it outlines the company’s governance and financial strategies moving forward.

Active Biotech AB Announces Annual General Meeting and Key Resolutions
Apr 28, 2025

Active Biotech AB has announced its upcoming Annual General Meeting scheduled for May 28, 2025, where shareholders will discuss various resolutions including the re-election of board members and the proposal to carry forward the company’s accumulated loss without paying dividends. The meeting will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the auditor, indicating a stable continuity in the company’s governance and financial oversight.

Active Biotech AB Announces 2025 Annual General Meeting Details
Apr 28, 2025

Active Biotech AB has announced its upcoming Annual General Meeting (AGM) scheduled for May 28, 2025. Key agenda items include the re-election of board members and auditors, with no dividend to be paid as the company’s accumulated loss will be carried forward. The meeting will also address board remuneration and share issue authorization, impacting the company’s governance and financial strategy moving forward.

Active Biotech AB Announces AGM and Key Resolutions
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address board remuneration and share issue authorization, reflecting the company’s strategic focus on maintaining financial stability and governance continuity.

Active Biotech AB Announces 2025 Annual General Meeting
Apr 28, 2025

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Shareholders are invited to participate, with key agenda items including the election of board members and auditors, and resolutions on the company’s financial statements. The board proposes no dividend distribution, opting to carry forward the accumulated loss, and recommends re-election of current board members and auditors.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025